Author

Nancy Wong

Observed name: N. Wong

Observed institutions: Sanofi (United States), Sanofi (Germany), Eisai (United States), Eisai (Japan)

OpenAlex ID: A5111534405

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

2009 · Sanjay Goel, Alain C. Mita, et al. · Clinical Cancer Research · 145

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

2022 · Alexander Röth, Sigbjørn Berentsen, et al. · Blood · 142

PDF

Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers

2004 · Daniel P. Rossignol, Kishor M. Wasan, et al. · Antimicrobial Agents and Chemotherapy · 73

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity

2016 · Krystyna M. Wozniak, James J. Vornov, et al. · Cancer Research · 52

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects: The Journal of Clinical Pharmacology

2013 · Yanke Yu, Veronika Logovinsky, et al. · The Journal of Clinical Pharmacology · 45

Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead

2009 · H. Du, T. Matsushima, et al. · Bioorganic & Medicinal Chemistry Letters · 28

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

2008 · Daniel P. Rossignol, Nancy Wong, et al. · Innate Immunity · 25

PDF

First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor

2023 · Timothy Chow, Pirouz Shamszad, et al. · Clinical and Translational Science · 23

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease

2023 · Thomas Frank, Andreas Kovar, et al. · Journal of Pharmacology and Experimental Therapeutics · 9

PDF

A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease

2025 · Sophie Susen, Marc Trossaërt, et al. · Journal of Thrombosis and Haemostasis · 8

PDF

Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits

2007 · Kishor M. Wasan, Verica Risovic, et al. · Pharmaceutical Research · 8

Pharmacokinetics (PK) of E7389, a Halichondrin B analog with novel anti-tubulin activity: Results of two phase I studies with different schedules of administration

2005 · N. Wong, C. Desjardins, et al. · Journal of Clinical Oncology · 8

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A

2025 · Nancy Wong, Pratik Bhagunde, et al. · The Journal of Clinical Pharmacology · 3

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

2023 · Flora Peyvandi, Cristina Tarango, et al. · Blood · 3

PDF

Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects

2021 · Suresh Katragadda, Srividya Neelakantan, et al. · The Journal of Clinical Pharmacology · 3

PDF

Abstract #3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts

2009 · Jiayi Wu, K. Nomoto, et al. · Cancer Research · 3

P1471: Sustained Efficacy of Sutimlimab, a Complement C1s Inhibitor, in Patients With Cold Agglutinin Disease: Results From Part B of the Phase 3 Cadenza Study

2023 · Alexander Röth, Sigbjørn Berentsen, et al. · HemaSphere · 1

Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK / PD and Exposure‐Response Analyses

2025 · Timothy Chow, Marek Wardecki, et al. · Clinical Pharmacology & Therapeutics

PDF

Population Pharmacokinetic/Pharmacodynamic Modeling and Simulation of a Flat Quarterly Riliprubart Dosing Regimen for Patients With Cold Agglutinin Disease

2024 · Tim Chow, Marek Wardecki, et al. · Journal of Pharmacology and Experimental Therapeutics

P1469: Inhibition of Complement C1s With Sutimlimab in Patients With Cold Agglutinin Disease (cad): Results Following 9-week Off-treatment Period (washout) in the Phase 3 Cadenza Study

2023 · Alexander Röth, Sigbjørn Berentsen, et al. · HemaSphere

Abstract 4653: Pharmacokinetics and biodistribution of eribulin mesylate, paclitaxel, and ixabepilone in mouse

2014 · Krystyna Wozniak, Ying Wu, et al. · Cancer Research

Works count: 21

Citation count: 579

H-index: 9

I10-index: 8